Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis
- 779 Downloads
The approval of etanercept for the treatment of the juvenile idiopathic arthritis (JIA) categories extended oligoarthritis (ExtOA), enthesitis-related arthritis (ERA) and psoriasis arthritis (PsA) was recently added to the approval for the treatment of polyarticular-course JIA (PA). This study aims to evaluate the efficacy and safety of etanercept in a large number of patients with the additional JIA categories. The Biologika in der Kinderrheumatologie (BIKER) registry documents baseline demographics, clinical characteristics and disease activity parameters. Efficacy was determined using the PedACR 30/50/70 response criteria and the Juvenile Arthritis Disease Activity Score (JADAS)-10. Safety assessments were based on adverse events’ reports. Until December 2012, a total of 1,678 JIA patients, incorporating 238 ERA, 315 ExtOA and 127 PsA patients were included. JADAS-10 demonstrated marked improvement compared to baseline after 3 to 24 months in ExtOA [16.1 ± 7.6 (baseline), 5.1 ± 5.2 (3 months), 3.0 ± 3.5 (24 months)]; ERA (15.3 ± 7.2, 4.4 ± 4.7, 4.0 ± 4.9) and PsA (14.7 ± 6.4, 5.0 ± 4.6, 5.3 ± 6.4). Compared to patients with PA, the rate of serious adverse events [relative risk (RR) 1.39 (0.95–2.03, p = 0.08)] and nonserious [1.18 (1.02–1.35; p = 0.03)] adverse events were elevated. The rate of uveitis flares was significantly higher in PsA (3.3/100 patient-years), ExtOA (2.8/100 patient-years) and ERA (2.7/100 patient-years) than in rheumatoid factor (RF)-negative polyarticular JIA (1.3/100 pat.yrs) or RF-positive polyarticular JIA (0.27/100 patient-years). Reports on chronic inflammatory bowel disease were numerically more frequent in ExtOA, ERA and PsA. Administration of etanercept in patients with the JIA categories ExtOA, ERA and PsA is safe and very efficacious in children. Attention should be paid to the occurrence of extraarticular autoimmunopathies.
KeywordsEfficacy Etanercept Juvenile idiopathic arthritis Safety Selected categories
The authors would like to thank all rheumatology centres in Germany and Austria participating in the BIKER registry.
Conflict of interest
DW declares grant/research support from Pfizer. GH declares grant/research support from Pfizer, AbbVie and Roche. TM and IB declare no competing interests.
The BIKER registry is funded by an unrestricted grant from Abbott/Abbvie, Wyeth/Pfizer and Roche/Chugai. The sponsors had no influence on study design, data analysis and/or manuscript writing. The submitted manuscript has not been discussed with the sponsors. Publication was not established as a contractual part of the sponsoring.
- 11.Horneff G, Burgos-Vargas R, Constantin T et al (2013) Efficacy and safety of open label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: part 1(week 12) of the CLIPPER study. Ann Rheum Dis. doi: 10.1136/annrheumdis-2012-203046 PubMedCentralPubMedGoogle Scholar
- 13.Foeldvari I, Ruperto N, Dressler F et al (2001) The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 19(4 Suppl 23):71–75Google Scholar
- 17.Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology Appraisal No.35 National Institute for Health and Care Excellence. 1-24 March 2002 (review January 2005). www.nice.org.uk
- 18.Lovell DJ, Giannini EH, Reiff A et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763–769Google Scholar
- 20.Sticherling M, Minden K, Küster RM, Krause A, Borte M (2007) Psoriasis und Psoriasisarthritis im Kindes- und Jugendalter. Zeitschr Rheum 66(4):349–354Google Scholar
- 22.Horneff G, Fitter S, Foeldvari I et al. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 2012 Oct 24;14(5):R230Google Scholar
- 25.Heiligenhaus A, Niewerth M, Ganser G, Heinz C, Minden K (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46(6):1015–1019CrossRefGoogle Scholar
- 28.van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM (2011) Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept. J Rheumatol 38(7):1441–1446PubMedCrossRefGoogle Scholar